Response to chemotherapy improves hepatic reserve for patients with hepatocellular carcinoma and Child–Pugh B cirrhosis

Takeshi Terashima,1,2 Tatsuya Yamashita,2 Kuniaki Arai,1 Kazunori Kawaguchi,1 Kazuya Kitamura,2 Taro Yamashita,2 Yoshio Sakai,1 Eishiro Mizukoshi,1 Masao Honda1 and Shuichi Kaneko1

1Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa; 2Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan

Key words
Child–Pugh class B, hepatic arterial infusion chemotherapy, hepatic reserve, hepatocellular carcinoma, response to chemotherapy

Correspondence
Tatsuya Yamashita, Department of Gastroenterology, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa-shi, Ishikawa 920-8641, Japan.
Tel: +81-76-234-2232; Fax: +81-76-234-4250;
E-mail: ytatsuya@m-kanazawa.jp

Funding Information
No sources of funding were declared in this study.

Received March 3, 2016; Revised May 31, 2016; Accepted June 14, 2016
Cancer Sci 107 (2016) 1263–1269
doi: 10.1111/cas.12992

Epithelial carcinoma (HCC) remains a health concern worldwide because its incidence continues to increase.1 Despite recent advances in diagnostic and therapeutic technologies,2,3 patients with HCC who receive curative treatment frequently experience multicentric recurrence that is difficult to treat. Consequently, patients with advanced HCC have unsatisfactory outcomes.4

For patients without cirrhosis or with Child–Pugh class A cirrhosis, the results of a randomized trial establish sorafenib as the standard of care for patients with advanced HCC.5 In contrast, there is no established treatment for patients with advanced HCC with Child–Pugh class B cirrhosis. Sorafenib may be a treatment option for patients with Child–Pugh class B cirrhosis;6 however, the outcomes of these patients are worse compared with those with Child–Pugh class A.7–10 Therefore, the development of alternative treatments is essential.

Hepatic arterial infusion chemotherapy (HAIC) is a promising treatment for a certain number of patients with advanced HCC and is being administered in Asia in particular.11 However, for example, to our knowledge, there are no reports that evaluate the efficacy and feasibility of HAIC according to Child–Pugh scores (CPS) and change of CPS of patients with advanced HCC and Child–Pugh class B cirrhosis treated with HAIC. The efficacy of HAIC for those patients remains unclear.

There is no established treatment for patients with advanced hepatocellular carcinoma (HCC) with Child–Pugh class B cirrhosis. The aim of the present study was to assess the efficacy of hepatic arterial infusion chemotherapy (HAIC) according to Child–Pugh score (CPS) and to evaluate the correlation of a patient’s response to HAIC with hepatic reserve and outcome. We retrospectively reviewed the medical records of 377 patients treated with HAIC between March 2003 and February 2015. Subjects included 179 with Child–Pugh class B. Median overall survival was 12.1 months for patients with CPS = 7 (n = 75) and 11.9 months for patients with CPS = 8 (n = 58), which were significantly longer compared with those of patients with CPS = 9 (n = 46, 6.3 months). The objective response rates of patients with CPS = 7, 8 and 9 were 26.7%, 27.6% and 6.5%, respectively. The CPS of responders improved significantly after HAIC, whereas those of nonresponders did not. A multivariate analysis demonstrated that improved CPS, responses to HAIC and absence of extrahepatic lesions were independent favorable prognostic factors. Patients with CPS = 7 or 8 tolerated HAIC, but nine (19.6%) of patients with CPS = 9 were unable to complete one course. HAIC is effective and safe for patients with a CPS = 7 or 8 and improved hepatic reserve of responders significantly.

The aim of the present study was to determine the efficacy of HAIC for treating patients with advanced HCC with Child–Pugh class B. Moreover, we investigated the effect of patients’ responses to treatment on their outcomes and hepatic reserves.

Materials and Methods

Objective patients. We studied consecutive patients with advanced HCC who were treated with HAIC at the Kanazawa University Hospital from March 2003 to February 2015. Because the radiological findings of these patients included vascular invasion and/or intrahepatic multiple lesions, they were judged to be unsuitable for surgical resection, locoregional therapy and transarterial chemoembolization. All patients underwent dynamic computed tomography or dynamic magnetic resonance imaging, and HCC was diagnosed according to the guidelines of the American Association for the Study of Liver Disease.12 Patients with extrahepatic lesions were eligible for HAIC if their extrahepatic lesions were mild and judged not to be prognostic (i.e. small tumor burden, slowly growing tumor, and no effect of the tumor on patients’ symptoms).

Hepatic arterial infusion chemotherapy. The implantation of the reservoir system to deliver agents is performed as previously described.13 Briefly, catheters were induced through the right femoral artery, and angiography from the celiac artery...
was first performed to localize the HCC and evaluate intrahepatic and extrahepatic vascularization. We next inserted a catheter with the side opening into the gastroduodenal artery, positioning the side opening in the common hepatic artery using an image-guided procedure. The gastroduodenal artery, right gastric artery and other arteries that were suspected to nourish the gastroduodenal region were embolized to the extent possible to prevent gastrointestinal mucositis. The other end of the catheter was connected to the injection port that was implanted subcutaneously in the right-lower abdomen. Finally, we confirmed the redistribution of blood flow.

Hepatic arterial infusion chemotherapy was conducted after we confirmed the full recovery of the wound. The treatment protocol was as follows: 5-fluorouracil (330 mg/m²/day) was administered continuously from days 1 to 5 and days 8 to 12. Some patients received intravenous cisplatin (20 mg/m²/day) injected into the hepatic artery for 10 min before administration of 5-fluorouracil. Interferon α-2b or pegylated interferon α-2b was used at the physician’s discretion. Pegylated interferon α-2b (1.0 µg/kg) was administered subcutaneously on days 1, 8, 15 and 22, and interferon-2b (3 x 10^8 U) was administered intramuscularly three times each week. The drugs were administered for a treatment cycle of 28 days followed by a 14-day rest period. The treatment was repeated until tumor progression, unacceptable toxicity, patient refusal of treatment, or death.

Assessment of response to treatment. The efficacy of treatment was assessed every 4–6 weeks using dynamic computed tomography or dynamic magnetic resonance imaging during and after treatment. The antitumor effect of treatment was assessed according to the Response Evaluation Criteria in Solid Tumors version 1.1.[14] The Child–Pugh score was assessed every visit using physiological and laboratory findings. Overall survival (OS) was defined as the start of treatment until death. Progression-free survival (PFS) was defined as the start of treatment until the date of radiological progression, death, or the last day of follow-up. An objective response rate was defined as the sum of the complete response rate and the partial response rate.

Data collection. We reviewed patients’ medical records and collected demographic, clinical and laboratory data, which included age, sex, Eastern Cooperative Oncology Group performance status, hepatitis virus status, hepatic reserve, imaging data (vascular invasion and extrahepatic lesions) and analyses of tumor markers. The institutional review board of Kanazawa University Hospital approved the study’s treatment strategy and study protocol. The study was conducted in accordance with the Declaration of Helsinki.

Statistical analysis. Categorical variables were compared using the χ²-test when appropriate. The Student t-test and the Mann–Whitney test were used for continuous variables. Cumulative survival was calculated using the Kaplan–Meier method to evaluate the association of clinical factors with survival, and differences were evaluated using the log-rank test. Multivariate analysis using Cox’s proportional hazards regression model was used to determine the hazard ratios for risk factors associated with OS. All statistical analyses were performed using the SPSS statistical software program (version 21.0; SPSS, Chicago, OH, USA).

Results

Characteristics of the patients treated with hepatic arterial infusion chemotherapy. Between March 2003 and February 2015, 377 patients were treated with HAIC, and data were collected until 14 March 2015. The median follow-up period was 8.48 (range, 0.23–141.14) months. The Child–Pugh classifications of patients when HAIC commenced were as follows: A, 151 (40.1%); B, 179 (47.5%); and C, 47 (12.5%). Among the patients with Child–Pugh class B, CPS were as follows: CPS = 7, 75 (41.9%); CPS = 8, 58 (32.4%) and CPS = 9, 46 (25.7%). More patients with worse Child-Pugh classification had a statistically significant increase in vascular invasion, extrahepatic spread and α-fetoprotein (AFP) ≥400 ng/mL; and more patients with worse Child-Pugh classification had more advanced stages of HCC according to the criteria of the Liver Cancer Study Group of Japan (Table 1). Patients with CPS = 9 were younger and had worse performance status compared with patients with CPS = 7 or 8 (Table 2). Other patient demographic characteristics are summarized in Tables 1 and 2. At the time of the analysis, 291 patients (77.2%) were deceased. The 377 patients completed a total of 965 courses of treatment, with a median of 2 (range, 0–31). Eighteen patients (10.1%), including three patients (4.0%) with CPS = 7, six patients (10.3%) with CPS = 8, and nine patients (19.6%) with CPS = 9, were unable to complete at least one course of HAIC because of unacceptable toxicities, worse general condition or tumor progression.

Progression-free survival and overall survival of patients treated with hepatic arterial infusion chemotherapy stratified according to Child–Pugh score. The median PFS was 4.8, 4.1 or 1.4 months for patients with Child–Pugh class A, B or C, respectively (Fig. 1a). The median PFS was 4.8, 4.9 and 1.7 months for patients with CPS = 7, 8 and 9, respectively.

**Table 1.** Demographic characteristic of the patients according to Child–Pugh classification

| Child–Pugh class | A (n = 151) | B (n = 179) | C (n = 47) | P-value* |
|------------------|-------------|-------------|------------|----------|
| Age, n (%)       |             |             |            |          |
| ≥66              | 88 (58.3)   | 93 (52.0)   | 16 (34.0)  | 0.015    |
| Sex, n (%)       |             |             |            |          |
| Male             | 123 (81.5)  | 135 (75.4)  | 37 (78.7)  | 0.41     |
| ECOG PS, n (%)   |             |             |            |          |
| 0                | 140 (92.7)  | 130 (72.6)  | 29 (61.7)  | <0.01    |
| 1                | 11 (7.3)    | 44 (24.6)   | 11 (23.4)  |          |
| ≥2               | 0           | 5 (2.8)     | 7 (14.9)   |          |
| HB antigen, n (%)|             |             |            |          |
| Positive         | 40 (26.5)   | 42 (23.5)   | 17 (36.2)  | 0.21     |
| HCV antibody, n (%)|            |             |            |          |
| Positive         | 78 (51.7)   | 98 (54.7)   | 22 (46.8)  | 0.60     |
| Negative         | 73 (48.3)   | 81 (45.3)   | 25 (53.2)  |          |
| Vascular invasion, n (%)|       |             |            |          |
| Positive         | 64 (42.4)   | 93 (52.0)   | 31 (66.0)  | 0.014    |
| Negative         | 78 (57.6)   | 87 (48.0)   | 26 (34.0)  |          |
| Extrahepatic spread, n (%)|   |             |            | 0.025    |
| Positive         | 29 (19.2)   | 48 (26.8)   | 18 (38.3)  |          |
| Negative         | 122 (80.8)  | 131 (73.2)  | 30 (61.7)  |          |
| LCSGJ tumor stage, n (%)|       |             |            | 0.064    |
| II, III          | 85 (56.3)   | 85 (47.5)   | 16 (34.0)  |          |
| IVA              | 47 (31.1)   | 56 (31.3)   | 16 (34.0)  |          |
| IVB              | 19 (12.6)   | 38 (21.2)   | 15 (31.9)  |          |
| AFP, n (%)       |             |             |            |          |
| ≥400 ng/mL       | 59 (39.1)   | 91 (50.8)   | 32 (68.1)  | <0.01    |

*χ²-test. AFP, α-fetoprotein; ECOG PS, Eastern Cooperative Oncology Group performance status; HB antigen, hepatitis B virus surface antigen; HCV antibody, hepatitis C virus antibody; LCSGJ, Liver Cancer Study Group of Japan.
The PFS of patients with CPS = 7 and 8 was significantly better compared with that of patients with CPS = 9 (P = 0.024 and P = 0.011 compared with CPS = 7 and 8, respectively) (Fig. 1b).

The median OS was 15.5, 9.9 and 2.9 months for patients with Child–Pugh class A, B and C, respectively (Fig. 2a). The median OS was 12.1, 11.9 and 6.3 months for patients with CPS = 7, 8 and 9, respectively. The OS of patients with CPS = 7 and 8 was significantly better compared with that of patients with CPS = 9 (P = 0.015 and P = 0.043 compared with CPS = 7 and 8, respectively) (Fig. 2b).

Objective response to with hepatic arterial infusion chemotherapy according to Child–Pugh score. The objective responses to HAIC were 33.8%, 21.8% and 6.4% for patients with Child–Pugh class A, B and C, respectively. For patients with CPS = 7, 8 and 9, their objective responses to HAIC were 26.7%, 27.6% and 6.5%, respectively (Table 3). The objective responses of patients with CPS of 7 and 8 were significantly better compared with those of patients with CPS = 9 (P < 0.01 and P < 0.01 compared with CPS = 7 and 8, respectively) (Table 4).

Analysis of Child–Pugh score of patients with Child–Pugh class B stratified according to their responses to hepatic arterial infusion chemotherapy. Among patients with Child–Pugh class B, CPS data were available for 173 and 130 patients at 4 and 12 weeks, respectively, after HAIC started (Table S1). Among patients with CPS = 7 when HAIC commenced, the CPS significantly improved for responders to 6.45 after 4 weeks (P < 0.01), which was maintained after 12 weeks (the mean CPS 6.30, P < 0.01). In contrast, the CPS did not improve for those whose best antitumor effect was stable disease; the mean CPS after 4 and 12 weeks were 7.17 and 7.36, respectively, among the patients with CPS = 7 when HAIC commenced (P = 0.58 and 0.10, respectively). Moreover, the CPS became worse for those whose best antitumor effect was progressive disease or not evaluable; the mean CPS after 4 and 12 weeks were 7.38 and 7.88, respectively, among the patients with CPS = 7 when HAIC commenced (P = 0.18 and 0.038, respectively) (Fig. 3). Among patients with a CPS = 8 or 9 when HAIC commenced, the improvement of CPS for responders was similar to those of patients with CPS = 7 (Table S1).

Effects of hepatic arterial infusion chemotherapy on the Child–Pugh score of patients with main portal vein tumor thrombus. Among patients with Child–Pugh class B, 59 had main portal vein tumor thrombus when HAIC commenced. Nine patients responded to HAIC, and the best antitumor effect was stable disease for 17 patients. The other 33 patients had

Table 2. Demographic characteristic of the patients with Child–Pugh B according to Child–Pugh score

| Child–Pugh score | 7 (n = 75) | 8 (n = 58) | 9 (n = 46) | P-value* |
|------------------|-----------|-----------|-----------|----------|
| Age, n (%)       |           |           |           |          |
| >66              | 46 (61.3) | 29 (50.0) | 18 (39.1) | 0.056    |
| Sex, n (%)       |           |           |           |          |
| Male             | 57 (76.0) | 39 (67.2) | 39 (84.8) | 0.12     |
| ECOG PS, n (%)   |           |           |           |          |
| 0                | 55 (73.3) | 46 (79.3) | 29 (63.0) | 0.038    |
| 1                | 20 (26.7) | 11 (19.0) | 13 (28.3) |           |
| ≥2               | 0         | 1 (1.7)   | 4 (8.7)   |           |
| HBs antigen, n (%) |         |           |           |          |
| Positive         | 16 (21.3) | 16 (27.6) | 10 (21.7) | 0.67     |
| HCV antibody, n (%) |         |           |           |          |
| Positive         | 39 (52.0) | 33 (56.9) | 26 (56.5) | 0.82     |
| Vascular invasion, n (%) |     |           |           |          |
| Positive         | 36 (48.0) | 31 (53.4) | 26 (56.5) | 0.64     |
| Extrahepatic spread, n (%) |     |           |           |          |
| Positive         | 21 (28.0) | 13 (22.4) | 14 (30.4) | 0.63     |
| LCSGJ tumor stage, n (%) |     |           |           |          |
| II, III          | 40 (53.3) | 28 (48.3) | 17 (37.0) | 0.68     |
| IVA              | 20 (26.7) | 17 (29.3) | 19 (41.3) |           |
| IVB              | 15 (20.0) | 13 (22.4) | 10 (21.7) |           |
| AFP, n (%)       |           |           |           |          |
| ≥400 ng/mL       | 43 (57.3) | 25 (43.1) | 23 (50.0) | 0.26     |

*: χ²-test. AFP, α-fetoprotein; ECOG PS, Eastern Cooperative Oncology Group performance status; HB antigen, hepatitis B virus surface antigen; HCV antibody, hepatitis C virus antibody; LCSGJ, Liver Cancer Study Group of Japan.
(b) The median overall survival of the patients with Child–Pugh score 9 was 12.1 months, which was significantly better compared with that of patients with Child–Pugh score 8 was 11.9 months, which was significantly better compared with that of patients with Child–Pugh score 7. The mean Child–Pugh score did not improve. For patients whose best antitumor effects were stable (squares and gray line), the mean Child–Pugh score became worse.

Fig. 2. Kaplan–Meier plot of overall survival after hepatic arterial infusion chemotherapy commenced, according to Child–Pugh class and Child–Pugh score. (a) The median overall survival was 15.5, 9.9 or 2.9 months for patients with Child–Pugh class A, B and C, respectively. (b) The median overall survival of the patients with Child–Pugh score = 7 was 12.1 months, which was significantly better compared with that of patients with Child–Pugh score = 9, 6.3 months (P = 0.015). The median overall survival of patients with Child–Pugh score = 8 was 11.9 months, which was significantly better compared with that of patients with Child–Pugh score = 9 (P = 0.043).

Table 3. Objective responses to hepatic arterial infusion chemotherapy according to Child–Pugh classification

| Response† to hepatic arterial infusion chemotherapy | Child–Pugh class A (n = 151) | Child–Pugh class B (n = 179) | Child–Pugh class C (n = 47) |
|-----------------------------------------------|-----------------------------|-----------------------------|-----------------------------|
| Complete response                             | 12 (7.9%)                   | 5 (2.8%)                    | 1 (2.1%)                    |
| Partial response                               | 39 (25.8%)                  | 34 (19.0%)                  | 2 (4.3%)                    |
| Stable disease                                 | 54 (35.8%)                  | 62 (34.6%)                  | 13 (27.7%)                  |
| Progressive disease                            | 42 (27.8%)                  | 63 (35.2%)                  | 18 (38.3%)                  |
| Not evaluated                                  | 4 (2.6%)                    | 15 (8.4%)                   | 13 (27.7%)                  |
| Objective response rate                         | 33.8%                       | 21.8%                       | 6.4%                        |

Data are presented as N (%). †Based on RECIST v1.1.
commenced, and the mean albumin levels of patients with progressive disease or those who were not evaluable were 2.96 (±0.44) when HAIC commenced, and 2.83 (±0.58) 12 weeks after HAIC commenced.

Effects of with hepatic arterial infusion chemotherapy on overall survival and Child–Pugh score. When OS was stratified according to patients’ responses to HAIC, those of responders were significantly better compared with those of patients with stable or progressive disease according to RECIST v1.1 (P < 0.001 and P < 0.001, respectively) (Fig. 5a). The median OS of responders was 28.7 months, whereas that of the patients with progressive disease or those who were not evaluable was 13.6, 13.2 or 5.0 months, respectively. Similarly, the OS of the patients with improved or unchanged CPS was significantly better compared with patients with worsened CPS (P = 0.041 and P = 0.048) (Fig. 5b). The median OS values of patients with improved, unchanged and worsened CPS were 13.6, 13.2 and 4.3 months, respectively. Improved CPS (hazard ratio compared with worsened CPS, 0.609; P = 0.030), response to HAIC (hazard ratio compared with progressive disease, 0.223; P < 0.001), stable disease (hazard ratio, 0.537; P = 0.0031), and absence of extrahepatic lesions (hazard ratio 0.543; P = 0.005) were identified as independent factors for favorable prognosis using a multivariate Cox regression model (Table 5).

Discussion

Chronic liver disease is the underlying pathological condition of most patients with HCC, and impaired hepatic reserve caused by chronic liver disease often adversely affects a patient’s outcome and quality of life. Moreover, unlike other types of cancer, a patient’s outcome strongly depends on hepatic reserve as well as tumor factors which can be reflected by tumor markers such as serum AFP levels.

Novel targeted agents have been developed for patients with advanced HCC, including drugs which are being investigated in the late-phase clinical trials. However, the study populations are restricted to patients with sufficient hepatic reserve, namely Child–Pugh class A, or those without detectable liver cirrhosis. These selective criteria were imposed because of the difficulty in analyzing patients with impaired hepatic reserve. Furthermore, our present findings indicate that the development of HCC, which was characterized according to progressive intrahepatic lesions and portal vein tumor thrombus, affected patients’ hepatic reserve and that patients with more advanced stages of HCC had increased impairment of hepatic reserve (Table 1). At least 50% of the patients who underwent HAIC were diagnosed with Child–Pugh class B. Therefore, more effective treatment strategies are urgently required to improve the outcomes of patients with advanced HCC and Child–Pugh class B cirrhosis.
patients with CPS = 9 were significantly worse compared with those with Child–Pugh class A or CPS = 7 or 8 and were equal to those with Child–Pugh class C. Moreover, the high rate of discontinuation (approximately 20%) during the first course of HAIC demands careful attention for patients with CPS = 9 and suggests that appropriate candidates for HAIC were patients with a CPS 8 or better. In contrast, for patients with a CPS 9 or worse, the efficacy of HAIC was very limited, and patients' outcomes were very poor.

The most important insight provided by our current study is that a response to HAIC improved hepatic reserve, which contributed to prolonging survival. In previous reports, the clinical benefit of a response to treatment has been only assessed in the context of survival prolongation. To our knowledge, the present study is the first to demonstrate a significant merit to hepatic reserve by HAIC treatment to HCC and the influence of the improvement of hepatic reserve. Progressive intrahepatic lesions and portal vein tumor thrombus can often lead to impairment of hepatic reserve in part, as described above. For example, a main portal vein tumor thrombus may disturb portal blood flow and adversely affect liver function, which is consistent with our findings, because shrinkage of the lesions contributes to the improving hepatic reserve by mitigating the effects of tumor ligation or improvement of hepatic reserve. Moreover, improvement of hepatic reserve may increase treatment options, such as administering sorafenib to patients with Child–Pugh class A. Thus, such therapies can contribute to controlling tumor progression, although sufficient hepatic reserve is a favorable prognostic factor itself. The treatment for patients with advanced HCC should aim at relief from discomfort due to the impaired hepatic function as well as outcomes of survival. Hepatic reserve closely correlates with quality of life of patients with chronic liver disease. Therefore, HAIC may improve the quality of life and prolong the survival of patients with HCC, although no definite data other than for hepatic reserve was assessable here.

In conclusion, HAIC is effective for treating patients with advanced HCC with a CPS = 7 or 8. The CPS of responders also improved their outcomes, compared to nonresponders. Although the present study is limited due to the retrospective design and subjects, who were treated in a single center, our findings are informative for determining treatment strategies or designing future clinical trials of agents to treat patients with advanced HCC.

Disclosure Statement

The authors have no conflict of interest to declare.

References

1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7–30.
2 Lee JM, Yoon JH, Kim KW. Diagnosis of hepatocellular carcinoma: newer radiological tools. Semin Oncol 2012; 39: 399–409.
3 Song MJ, Chun HJ, Song do S et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57: 1244–50.
4 Yamashita T, Arai K, Sunogazaka H et al. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology 2011; 81: 281–90.

Table 5. Contributing factors to patients’ outcome

| N    | Median overall survival (months) | Hazard ratio (95% CI) | Multivariate P-value |
|------|---------------------------------|-----------------------|----------------------|
| CPS 4 weeks after HAIC | | | |
| Worsened | 45 | 4.3 | 0.728 (0.460–1.152) | 0.18 |
| or not evaluable | | | |
| Unchanged | 59 | 13.2 | 0.543 (0.356–0.829) | 0.054 |
| Improved | 69 | 13.6 | 0.537 (0.356–0.811) | 0.0031 |
| Vascular invasion | | | |
| Presence | 93 | 7.0 | 0.223 (0.136–0.366) | <0.001 |
| Absence | 86 | 15.4 | 0.775 (0.523–1.149) | 0.18 |
| Extrahepatic lesion | | | |
| Presence | 48 | 5.8 | 0.0046 |
| Absence | 131 | 13.6 | 0.543 (0.356–0.829) | 0.054 |
| AFP, ng/mL | | | |
| ≥400 | 91 | 7.3 | 0.0046 |
| <400 | 88 | 13.7 | 0.675 (0.452–1.007) | 0.054 |
| Best response to HAIC | | | |
| Progressive disease or not evaluable | 83 | 5.0 | |
| Stable disease | 57 | 13.6 | 0.537 (0.356–0.811) | 0.0031 |
| Complete response or partial response | 39 | 28.7 | 0.223 (0.136–0.366) | <0.001 |

AFP, α-fetoprotein; CI, confidence interval; CPS, Child–Pugh score; HAIC, hepatic arterial infusion chemotherapy. *Cox’s proportional hazards regression model.

In an attempt to overcome this difficult challenge, the first aim of the present study was to investigate the feasibility and efficacy of HAIC according to detailed CPS in patients with Child–Pugh class B. Published studies of small numbers of patients with advanced HCC and Child–Pugh class B who underwent HAIC did not analyze the relationship of efficacy or tolerability to every aspect of the CPS. They concluded that the effect of HAIC, according to response or time to progression of patients with Child–Pugh class B, was comparable with that of patients with Child–Pugh class A. In contrast, the OS of the patients with Child–Pugh class B was worse compared with those with Child–Pugh class A. Our present findings are consistent with those of the reports for patients with a CPS = 7 or 8, however, the responses to HAIC and the outcomes of patients with CPS = 9 were significantly worse compared with those with Child–Pugh class A or CPS = 7 or 8 and were equal to those with Child–Pugh class C. Moreover, the high rate of discontinuation (approximately 20%) during the first course of HAIC demands careful attention for patients with CPS = 9 and suggests that appropriate candidates for HAIC were patients with a CPS 8 or better. In contrast, for patients with a CPS 9 or worse, the efficacy of HAIC was very limited, and patients’ outcomes were very poor.

The most important insight provided by our current study is that a response to HAIC improved hepatic reserve, which contributed to prolonging survival. In previous reports, the clinical benefit of a response to treatment has been only assessed in the context of survival prolongation. To our knowledge, the present study is the first to demonstrate a significant merit to hepatic reserve by HAIC treatment to HCC and the influence of the improvement of hepatic reserve. Progressive intrahepatic lesions and portal vein tumor thrombus can often lead to impairment of hepatic reserve in part, as described above. For example, a main portal vein tumor thrombus may disturb portal blood flow and adversely affect liver function, which is consistent with our findings, because shrinkage of the lesions contributes to the improving hepatic reserve by mitigating the effects of tumor ligation or improvement of hepatic reserve. Moreover, improvement of hepatic reserve may increase treatment options, such as administering sorafenib to patients with Child–Pugh class A. Thus, such therapies can contribute to controlling tumor progression, although sufficient hepatic reserve is a favorable prognostic factor itself. The treatment for patients with advanced HCC should aim at relief from discomfort due to the impaired hepatic function as well as outcomes of survival. Hepatic reserve closely correlates with quality of life of patients with chronic liver disease. Therefore, HAIC may improve the quality of life and prolong the survival of patients with HCC, although no definite data other than for hepatic reserve was assessable here.

In conclusion, HAIC is effective for treating patients with advanced HCC with a CPS = 7 or 8. The CPS of responders also improved their outcomes, compared to nonresponders. Although the present study is limited due to the retrospective design and subjects, who were treated in a single center, our findings are informative for determining treatment strategies or designing future clinical trials of agents to treat patients with advanced HCC.

Disclosure Statement

The authors have no conflict of interest to declare.

References

1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7–30.
2 Lee JM, Yoon JH, Kim KW. Diagnosis of hepatocellular carcinoma: newer radiological tools. Semin Oncol 2012; 39: 399–409.
3 Song MJ, Chun HJ, Song do S et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57: 1244–50.
4 Yamashita T, Arai K, Sunogazaka H et al. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology 2011; 81: 281–90.
5 Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–90.
6 Lencioni R, Kudo M, Ye SL et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafenib): second interim analysis. Int J Clin Pract 2014; 68: 609–17.
7 Abou-Alfa GK, Amadori D, Santoro A et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest Cancer Res 2011; 4: 40–4.
8 Presssian T, Boni C, Rimassa L et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol 2013; 24: 406–11.
9 Kaneko S, Furuse J, Kudo M et al. Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update. Hepatol Res 2012; 42: 523–42.

© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Supporting Information

Additional Supporting Information may be found online in the supporting information tab for this article:

Table S1. Changes of Child–Pugh score according to response to hepatic arterial infusion chemotherapy

Table S2. Changes of Child–Pugh score according to response to hepatic arterial infusion chemotherapy among the patients with main portal vein tumor thrombus